Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.52 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.52 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | NMT2 | O60551 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20813199 | 0.89 | HPGD (0.54) | ANPEPDNPEPRNPEPHPGDLMNA | |
| Trifluoroacetic Acid SCHEMBL10693346 | 0.87 | ANPEP (0.42) | ANPEPDNPEPRNPEPHPGDLMNA | |
| SCHEMBL7947948 | 0.87 | KMT2A (0.41) | ANPEPDNPEPRNPEPHPGDLMNA | |
| SCHEMBL7936587 | 0.85 | KMT2A (0.45) | ANPEPDNPEPRNPEPHPGDLMNA | |
| SCHEMBL445146 | 0.83 | LMNA (0.54) | ANPEPDNPEPRNPEPHPGDLMNA | |
| SCHEMBL7257878 | 0.81 | ALDH1A1 (0.58) | ANPEPDNPEPRNPEPHPGDLMNA | |
| SCHEMBL22844861 | 0.80 | HPGD (0.41) | ANPEPDNPEPRNPEPHPGDLMNA | |
| SCHEMBL20810914 | 0.79 | LMNA (0.55) | ANPEPDNPEPRNPEPHPGDLMNA | |
| SCHEMBL22845584 | 0.79 | MEN1 (0.49) | ANPEPDNPEPRNPEPHPGDALDH1A1 | |
| SCHEMBL16384812 | 0.79 | LMNA (0.46) | ANPEPDNPEPRNPEPHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023215740-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| US-10660939-B2 | Therapies for obesity, diabetes and related indications | PALATIN TECHNOLOGIES, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20180153965-A1 | Therapies for Obesity, Diabetes and Related Indications | PALATIN TECHNOLOGIES INC (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180153965-A1 | Therapies for Obesity, Diabetes and Related Indications | PALATIN TECHNOLOGIES INC (US) | 2018-06-07 | — | — | US | disclosed |
| US-20100003276-A1 | Methods for treating anthrax and inhibiting lethal factor | HERMES JEFFERY D | 2010-01-07 | — | — | US | disclosed |
| US-7504425-B2 | Compounds useful in the treatment of anthrax and inhibiting lethal factor | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| WO-2007100374-A9 | SOFT PROTEASE INHIBITORS AND PRO-SOFT FORMS THEREOF | TUFTS COLLEGE (US) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007100374-A2 | SOFT PROTEASE INHIBITORS AND PRO-SOFT FORMS THEREOF | TRUSTEES OF TUFTS COLLEGE (US) | 2007-09-07 | — | — | WO | disclosed |
| EP-0082088-B1 | DERIVATIVES OF AMINO ACIDS AND THEIR THERAPEUTIC USE | Roques, Bernard (FR) | 1986-04-02 | — | — | EP | disclosed |
| EP-0082088-A1 | Derivatives of amino acids and their therapeutic use | Roques, Bernard (FR) | 1983-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003276-A1 | Methods for treating anthrax and inhibiting lethal factor | ANTXR2, SERPINB1, APAF1 | ANPEP 179/4885DNPEP 303/4885RNPEP 141/4885 |
| US-10660939-B2 | Therapies for obesity, diabetes and related indications | MC4R, GLP1R, MC3R | ANPEP 1137/4885DNPEP 1147/4885RNPEP 1143/4885 |
| US-20180153965-A1 | Therapies for Obesity, Diabetes and Related Indications | MC4R, GLP1R, MC3R | ANPEP 1137/4885DNPEP 1147/4885RNPEP 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.